ArticleNature communications2021

Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers.

David H Peng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.